Trodelvy fails PhIII lung cancer study in blow to Gilead’s ADC expansion plans

Gilead’s an­ti­body-drug con­ju­gate Trodelvy failed to sig­nif­i­cant­ly ex­tend sur­vival in a late-stage lung can­cer study, the phar­ma com­pa­ny said Mon­day morn­ing.

The Phase III EVOKE-01 study looked at Trodelvy in sec­ond-line metasta­t­ic non-small cell lung can­cer. It’s the first piv­otal read­out for the TROP2 an­ti­body-drug con­ju­gate in lung can­cer, a cat­e­go­ry that Gilead has eyed for Trodelvy. Gilead’s stock $GILD fell 10% in pre­mar­ket trad­ing Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.